Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E. Babenko
Retreatment With Nivolumab in Patients With R/R Classical Hodgkin Lymphoma After Discontinuation of the Therapy With Immune Checkpoint Inhibitors
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Retreatment With Immune Checkpoint Inhibitors in Solid Tumors: A Systematic Review
A First-In-Human Trial of the Novel Multi-Action Therapy Tinostamustine (Edo-S101) in Patients With Relapsed/Refractory (R/R) Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Concurrent Therapy With Immune Checkpoint Inhibitors and TNFα Blockade in Patients With Gastrointestinal Immune-Related Adverse Events
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements Towards New Perspectives
Journal of Oncology
Oncology
Recurrent Pneumonitis in Patients With Melanoma Treated With Immune Checkpoint Inhibitors
Oncologist
Cancer Research
Medicine
Oncology
Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
REAL-WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) OF CLASSICAL HODGKIN LYMPHOMA (cHL) PATIENTS (PTS) TREATED WITH ANTI-PD1 CHECKPOINT INHIBITORS IN THE UNITED STATES (US)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology